PRESS RELEASE FROM
This press release is copyrighted to the journal Neuropsychopharmacology. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.
PLEASE CITE NEUROPSYCHOPHARMACOLOGY
AND THE NEUROPSYCHOPHARMACOLOGY
WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO www.nature.com/npp/
Genetic basis for antipsychotic-induced weight gain
People with certain variants of the cannabinoid receptor 1 gene (CNR1) are more likely to gain substantial amounts of weight on antipsychotic medications than those without these genetic variants, reports a study online this week in Neuropsychopharmacology. Antipsychotic medications have revolutionized the treatment of schizophrenia, but the associated weight gain experienced by some patients can create health complications and lead to less successful responses to treatment. This research could help identify those at risk.
To investigate a previously theorized link between CNR1 and weight regulation, James Kennedy, Daniel Mueller and colleagues analyzed DNA from 183 patients from mixed ancestries who underwent treatment for chronic schizophrenia. Analyses that controlled for ethnicity revealed an association between CNR1 variants and antipsychotic-induced weight gain for several gene loci.
If these results are replicated in a larger study, CNR1 variants could potentially be used to identify people who are susceptible to antipsychotic-induced weight gain and aid in the development of new schizophrenia medications that avoid this side effect.
James Kennedy (Center for Addiction and Mental Health, Ontario, Canada)
Tel: +1 416 979 4987; E-mail: James_Kennedy@camh.net
Daniel Müller (Center for Addiction and Mental Health, Ontario, Canada)
Tel: +1 416 979 4987; E-mail: Daniel_Mueller@camh.net Editorial contact:
Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: email@example.com